Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis-Reference-Cited by-同舟云学术

Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis

Published:2012-09-20 Issue:11 Volume:21 Page:1232-1239
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Miller Jessica E¹,Molnar Miklos Z¹²³,Kovesdy Csaba P⁴⁵,Zaritsky Joshua J⁶,Streja Elani¹,Salusky Isidro⁶,Arah Onyebuchi A⁷,Kalantar-Zadeh Kamyar¹⁸

Affiliation:

1. Harold Simmons Center for Chronic Disease Research and Epidemiology; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center; Torrance CA USA

2. Institute of Pathophysiology; Semmelweis University; Budapest Hungary

3. Department of Medicine, Division of Nephrology, University Health Network; University of Toronto; Toronto Ontario Canada

4. Division of Nephrology, Memphis Veterans Affairs Medical Center; Memphis TN USA

5. Division of Nephrology; University of Tennessee Health Science Center; Memphis TN USA

6. David Geffen School of Medicine at UCLA; Los Angeles CA USA

7. Department of Epidemiology; UCLA School of Public Health; Los Angeles CA USA

8. Division of Nephrology and Hypertension; University of California Irvine Medical Center; Orange CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pds.3349/fullpdf

Reference50 articles.

1. Chronic kidney disease-mineral-bone disorder: a new paradigm;Moe;Adv Chronic Kidney Dis,2007

2. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO);Moe;Kidney Int,2006

3. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease;Levin;Kidney Int,2007

4. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients;Ambrus;Int Urol Nephrol,2009

5. Bone mineral density and parathyroid function in patients on maintenance hemodialysis;Ambrus;Int Urol Nephrol,2011

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis

;Drug Design, Development and Therapy;2019-03

2. Assessing the effect of oral activated vitamin D on overall survival in hemodialysis patients: a landmark analysis;BMC Nephrology;2018-11-06

3. Vitamin D and methylarginines in chronic kidney disease (CKD);PLOS ONE;2017-10-04

4. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials;BMC Nephrology;2017-08-25

5. The Obesity Paradox in Kidney Disease: How to Reconcile It With Obesity Management;Kidney International Reports;2017-03